GSK’s Avandia monthly sales slide to 6 million won

Published: 2010-12-24 06:56:00

Updated: 2010-12-24 06:56:00

GlaxoSmithKline’s embattled diabetes drug Avandia has lost a lot of market ground in the market to competitors as a medicine for type 2 diabetes, even if the Korea Food and Drug Administration (KFDA) ordered doctors to refrain from prescribing it for type-2 diabetes patients last September.

Av...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK